Literature DB >> 225928

Angiotensin-converting enzyme in sarcoidosis.

F K Rømer.   

Abstract

Using a spectrophotometric assay with L-hippuryl-L-histidyl-L-leucine as substrate, s-angiotensin-converting enzyme (SACE) was determined in 85 sarcoidosis patients, 116 healthy controls and 150 patients with various non-sarcoid diseases. The controls showed no sex or age variation and had SACE levels of 24.4 +/- 6.2 U/ml (mean +/- 1 S.D.), giving a normal range (mean +/- 2 S.D.) of 12.0-36.8 U/ml. In contrast, the sarcoidosis patients had SACE values of 38.4 +/- 14.4 U/ml, with the highest values in cases with active sarcoidosis and duration of disease longer than two years (49.0 +/- 12.7 U/ml). A total of 41% of the sarcoidosis patients had elevated SACE, in the chronic active group 85%. Patients with renal failure, Hodgkin's disease and other malignant lymphoma had low SACE, whereas patients with lung cancer and tuberculosis had normal SACE values. Among 266 patients with non-sarcoid diseases and healthy controls, only two had slightly elevated SACE, but so far we have not found SACE above 40 U/ml in other than sarcoidosis patients. An elevated SACE is rather specific in sarcoidosis and seems to be a useful supplement to existing diagnostic measures.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 225928     DOI: 10.1111/j.0954-6820.1979.tb13464.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  11 in total

1.  In vitro synthesis of angiotensin-converting enzyme by alveolar macrophages is increased in disseminated sarcoidosis.

Authors:  G Stanislas-Leguern; M Mordelet-Dambrine; D Dusser; M Huesca; J Chretien; G J Huchon
Journal:  Lung       Date:  1986       Impact factor: 2.584

2.  [Angiotensin-converting enzyme (ACE). Increased serum activities in patients with dermatological diseases (author's transl)].

Authors:  M Raff; H Bardach; M M Müller
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

Review 3.  Serum angiotensin converting enzyme in pulmonary disease.

Authors:  P K Rohatgi
Journal:  Lung       Date:  1982       Impact factor: 2.584

4.  Changes of s-angiotensin-converting enzyme (SACE) during antituberculous chemotherapy.

Authors:  H Harving; F K Rømer
Journal:  Lung       Date:  1983       Impact factor: 2.584

5.  Serum angiotensin-converting enzyme in sarcoidosis and psoriasis.

Authors:  K Thestrup-Pedersen; F K Rømer; J H Jensen; H Brodthagen
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

6.  Evaluation of albumin-globulin ratio to confirm the clinical stages of sarcoidosis.

Authors:  A K Nandedkar; G C Royal; M A Nandedkar
Journal:  J Natl Med Assoc       Date:  1986-10       Impact factor: 1.798

7.  Studies of peripheral blood monocytes in pulmonary sarcoidosis.

Authors:  F K Rømer; S E Christiansen; K Kragballe; T Herlin; M Madsen
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

Review 8.  Angiotensin-converting enzyme and its clinical significance--a review.

Authors:  P R Studdy; R Lapworth; R Bird
Journal:  J Clin Pathol       Date:  1983-08       Impact factor: 3.411

9.  Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma.

Authors:  F K Rømer; K Emmertsen
Journal:  Br J Cancer       Date:  1980-08       Impact factor: 7.640

10.  Angiotensin-converting enzyme and its association with outcome in lung cancer.

Authors:  F K Rømer
Journal:  Br J Cancer       Date:  1981-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.